Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ‐Secretase Modulator
Annals of Neurology · 2023-08 · 94 (2) · 245-258
DOI: 10.1002/ana.26659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 29.04.2023. Verfasst von Xu-Qiao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Down Syndrome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: NIH HHS, NIA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
The retromer complex plays an essential role in intracellular endosomal sorting. Deficits in the retromer complex are linked to enhanced Aβ production. The levels of the components of the retromer complex are reported to be downregulated in Alzheimer disease (AD). Down syndrome (DS) shares neuropathological features with AD. Recent evidence points to dysregulation of the retromer complex in DS. The mechanisms underlying retromer deficits in DS and AD are poorly understood.
Methods
We measured the levels of retromer components in the frontal cortex of cases of DS‐AD (AD in DS) as well as DS; the frontal cortex of a person partially trisomic (PT‐DS) for human chromosome 21 (HSA21), whose genome had only the normal 2 copies of the APP gene, was also examined. We also analyzed these proteins in the Dp16 mouse model of DS. To further explore the molecular mechanism for changes in the retromer complex, we treated Dp16 mice with a γ‐secretase modulator (GSM; 776890), a treatment that reduces the levels of Aβ42 and Aβ40.
Results
We found VPS26A, VPS26B, and VPS29, but not VPS35, were significantly reduced in both DS and DS‐AD, but not in PT‐DS. Downregulation of VPS26A, VPS26B, and VPS29 was recapitulated in the brains of old Dp16 mice (at 16 months of age) and required increased App gene dose. Significantly, GSM treatment completely prevented reductions of the retromer complex.
Interpretation
Our studies point to increased APP gene dose as a compromising retromer function in DS and suggest a causal role for Aβ42 and Aβ40. ANN NEUROL 2023;94:245–258
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
- Genetics and Aging Research Unit, McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
ORCID-Profile: William C Mobley
Förderung
- NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Chen, X. Q., Sawa, M., Becker, A., Karachentsev, D., Zuo, X., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2023). Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ‐Secretase Modulator. Annals of Neurology, 94(2), 245-258. https://doi.org/10.1002/ana.26659
Vancouver
Chen XQ, Sawa M, Becker A, Karachentsev D, Zuo X, Rynearson KD, et al. Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ‐Secretase Modulator. Annals of Neurology. 2023;94(2):245-258. doi:10.1002/ana.26659
BibTeX
@article{Chen2023,
author = {Chen, Xu-Qiao and Sawa, Mariko and Becker, Ann and Karachentsev, Dmitry and Zuo, Xinxin and Rynearson, Kevin D and Tanzi, Rudolph E and Mobley, William C},
title = {Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ‐Secretase Modulator},
journal = {Annals of Neurology},
year = {2023},
volume = {94},
number = {2},
pages = {245--258},
doi = {10.1002/ana.26659}
}
EUVIMED